Xeltis to introduce aortic valve program at TCT 2016 New Technology Forum
Leading cardiologist Professor Christian M. Spaulding, Director of the Interventional Cardiology Department at European Hospital Georges Pompidou, will introduce Xeltis’ bioabsorbable aortic valve program as part of a design and clinical update at this year’s TCT 2016 meeting in Washington DC.
Professor Spaulding’s update on Xeltis’ technology is one of four presentations providing a specific design and clinical product update (Session II. TAVR 2016: Anatomic Decision-making and TAVR Systems II) on November 1st. Transcatheter Cardiovascular Therapeutics (TCT) is the world’s largest educational meeting specializing in interventional cardiovascular medicine, organized by the Cardiovascular Research Foundation.
“The aortic valve is a key focus for our company and we are making significant strides in its development,” said Laurent Grandidier. “Xeltis’ progress in the aortic valve space is an important addition to the recent announcement of clinical trial initiation for our pulmonary valve. Our plan is to further expand our pipeline in cardiovascular treatment.”
Click here for a detailed analysis of Xeltis developments by Medtech Strategist.